Currently there are no upcoming events.
The fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, held in New York City, is devoted to exploring the latest research in cancer immunology and immunotherapy.
Rational Combinations 360° is a comprehensive program providing exposure to the entire spectrum of research and development, addressing key aspects across all facets of combination immunotherapies.
CRI scientists are presenting at the Annual Meeting of the American Society of Clinical Oncologists. CRI is providing a daily recap of new work coming out of the conference.
This two-day scientific conference will convene experts in oncology and immunology to discuss emerging approaches, challenges, and opportunities faced in the rapidly evolving field of cancer immunotherapy.
Many CRI-funded and -affliated scientists and clinicans will be showcased at the American Association of Cancer Research Annual Meeting on April 14-18, 2018, in Chicago, Illinois.
On April 12, our chief medical officer, Aiman Shalabi, will be a featured expert on the panel, “Immuno-Oncology: Challenges & Opportunities”.
Dr. Jill O’Donnell-Tormey, CEO and director of scientific affairs, will participate in the 'Weaponizing Your Own Body' panel on Tuesday, March 20, 2018 at 7:45 am.
The fourth annual Immuno-Oncology 360° meeting will be held on February 7-9, 2018 at the Roosevelt Hotel, New York City.
Dr. Vanessa Lucey, associate director, CRI Venture Fund & Clinical Accelerator, is speaking during the "Back to Basics" session on January 23, 2018 at 2:00 p.m.
Aiman Shalabi, Chief Medical Officer, is a panelist at the ENDPOINTS Executive Breakfast in San Francisco. This year's topic: “Where is the cancer R&D revolution headed?”
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
The final day of CICON18 explored two diverse areas—technology and the microbiome—that both have the potential to improve immunotherapy’s benefits for patients.
The third day of CICON18 explored cutting-edge strategies to identify and target the mutated markers that distinguish cancer cells.